Rankin School of Nursing professor Dr. Donna Halperin receives two grants for vaccine research
StFX Rankin School of Nursing professor Dr. Donna Halperin is the successful recipient of two new Canadian Immunization Research Network (CIRN) grants that will help fund vaccine research.
CIRN has recently funded two new studies with Dr. Halperin, the co-principal investigator. The first project is funded for $300,481 over two years to research “Burden Ethnographic Modeling Evaluation Qaujilisaaqtuq (BEMEQ) RSV,” and she has been granted a further $150,010 to fund, “A multifaceted evaluation of provincial maternal Tdap immunization programs.”
Dr. Halperin says the multi-faceted evaluation of provincial maternal Tdap programs study is taking place in five provinces, which will inform the implementation of maternal Tdap (tetanus, diphtheria, and acellular pertussis) programs being rolled out across the country.
“The purpose of administering this vaccine is to protect newborn infants in Canada from severe outcomes of pertussis infection. Bordetella pertussis causes pertussis (Whooping Cough), a severe respiratory infection. Unimmunized infants, including those who are too young to have completed their primary infant immunization series, are at the greatest risk of hospitalization and death,” she says. “Immunization in pregnancy is safe and protects the infant until they are ready to receive the vaccine at two months of age.”
She says the focus of this study is to determine support and resources offered to health care providers for maternal Tdap programs and to identify gaps in learning needs according to provider type.
Also, she says knowledge, attitudes, and beliefs and behaviors (KABB) of pregnant women will be determined regarding the maternal Tdap vaccine. Three interventions will be developed; a practice intervention tool for providers and an information intervention and social marketing strategy directed towards pregnant women for maternal immunization. These three interventions will be evaluated for acceptability.
In the “Burden Ethnographic Modeling Evaluation Qaujilisaaqtuq (BEMEQ) RSV” study she says there has been the recent accelerated clinical development of Respiratory Syncytial Virus (RSV) vaccine candidates for pregnant women and children that offers the promise of RSV prevention.
“RSV is the most common cause of severe lower respiratory tract infection in young children worldwide. Exceedingly high rates are observed in the Canadian Arctic,” she says.
This study, which is situated in Nunavik (northern third of the province of Quebec) and Nunavut, will help inform public health planning by collecting data on RSV morbidity and health care use, careful modelling and economic analysis of the potential benefits of vaccines and an understanding of the acceptability of proposed interventions in target populations.
Dr. Halperin says there are three separate studies within the broader study, which brings together 28 investigators across Canada.
The focus of her portion of the study will be to describe the key determinants of vaccine acceptance and refusal at the demand side (values, attitudes, beliefs) and the access side (logistical, healthcare system factors impacting access and vaccine services) amongst parents, healthcare providers, educators, and public health practitioners. Sharing circles and key informant interviews will be used to collect this information in Nunavut, she says.
CIRN is funded by the Public Health Agency of Canada (PHAC) and the Canadian Institutes for Health Research (CIHR), and is a national network of vaccine researchers who develop and test methodologies related to the evaluation of vaccines as they pertain to safety, immunogenicity and effectiveness, and program implementation and evaluation.
CIRN is a network of networks, comprising eight sub-networks, composed of over 100 investigators across 40 Canadian institutions, involving experts in vaccine-related evaluative research.